SecBot SecBot
Biotech Drug Report Generated Jul 2, 2026

MT-002

INM·InMed Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Preclinical
Time to market
Unknown, preclinical stage; best-case scenario Phase 1 data in 2027, then Phase 2/3 would take several more years. Realistically 5+ years from now if successful.
Why 4/10
MT-002 is preclinical with no human data yet. The next hard catalyst is a first-in-human (FIH) regulatory filing expected Q1 2027. Since MT-002 is the secondary asset (behind MT-001) at a company undergoing a reverse merger, and the FIH filing is a non-binary regulatory submission rather than a pivotal readout, the impact on INM stock from MT-002 alone is limited near-term. The merger closing (target Dec 31, 2026) and MT-001's FIH filing (mid-2026) are more impactful near-term events.
Actionable Insight NEUTRAL

MT-002 is very early-stage and won't generate human data until at least late 2027. The nearer-term story for INM is the reverse merger with Mentari Therapeutics closing (target Q4 2026), the $290M PIPE funding, and MT-001's FIH filing. Existing INM shareholders face extreme dilution (~1.51% of the combined entity). This is a pre-revenue, preclinical-stage binary with a long timeline, not a trading catalyst in its own right.

Price Chart

Loading chart...

Executive Summary

MT-002 is a preclinical bispecific antibody targeting both CGRP and PACAP pathways for migraine prevention. It is the second pipeline asset (after MT-001) of Mentari Therapeutics, which is merging with micro-cap InMed Pharmaceuticals (INM) in a reverse merger backed by $290M in PIPE financing. MT-002 is potentially first-in-class as a dual-pathway inhibitor but is years away from human proof-of-concept, FIH filings aren't expected until Q1 2027, with Phase 1 data in 2027 at the earliest. The migraine prevention market is large (~$6.5-12B) but intensely competitive, with multiple approved anti-CGRP antibodies (Aimovig, Emgality, Ajovy, Vyepti) and Lundbeck's anti-PACAP antibody bocunebart already in Phase 2b with positive data. Existing INM shareholders are being diluted to ~1.51% of the combined entity, making this effectively a new company listing via reverse merger.

How It Works

MT-002 is a bispecific antibody, a single engineered protein designed to block two different biological targets at once. It targets both CGRP (calcitonin gene-related peptide) and PACAP (pituitary adenylate cyclase-activating polypeptide), two neuropeptides that are known to trigger migraine attacks. By blocking both pathways simultaneously, it aims to provide better migraine prevention than existing drugs that only block one of these targets. About two-thirds of migraine patients don't get adequate relief from current anti-CGRP-only drugs, so the dual mechanism is designed to help that population.

Trial Status

MT-002 is still in preclinical development. First-in-human (FIH) regulatory filings are expected in Q1 2027, with Phase 1 healthy volunteer data expected later in 2027. No clinical trials have been initiated yet. The drug was originally discovered by Paragon Therapeutics and is being developed by Mentari Therapeutics, which is merging into InMed Pharmaceuticals.

The Two-Sided Case

▲ Bull Case5
Potentially first-in-class bispecific antibody targeting two validated migraine pathways (CGRP and PACAP) simultaneously, could address the ~2/3 of patients with suboptimal response to existing anti-CGRP-only therapies.
Merger backed by $290M in committed PIPE financing from institutional investors, funding MT-001 and MT-002 programs through 2028, removing near-term cash concerns.
Massive addressable market: CGRP inhibitors market projected to reach $9-12.5B by 2033; MT-002 targets the large unmet need of non-responders.
Convenient subcutaneous dosing similar to marketed anti-CGRP antibodies, with potential for superior efficacy from dual pathway blockade.
Insider buying: 10% owner Vivo Opportunity, LLC purchased shares on the open market at ~$1.42-1.75 in June 2026, signaling confidence in the merged entity.
▼ Bear Case6
Preclinical, no human data yet; high risk of clinical failure. Only ~10% of preclinical CNS/migraine assets make it to FDA approval.
Existing INM shareholders diluted to ~1.51% of the combined company post-merger, the stock is essentially a new entity with a different business.
Intensely competitive landscape: 4 approved anti-CGRP antibodies (Aimovig, Emgality, Ajovy, Vyepti) plus oral gepants are entrenched, and Lundbeck's anti-PACAP antibody bocunebart (Lu AG09222) is already in Phase 2b with positive data, years ahead of MT-002.
Analyst consensus is bearish: 0 Buy, 3 Hold, 4 Sell, 1 Strong Sell. INM has no analyst price targets.
Micro-cap stock (~$4-5M market cap) with a history of distress: Nasdaq delisting notice in March 2026 (since resolved), and an amendment lowering option exercise price from $16.60 to $0.80, signaling financial strain pre-merger.
First-in-human data for MT-002 not expected until at least late 2027, very long timeline for a binary catalyst.

Upcoming Catalysts

  • Q3-Q4 2026: MT-001 (anti-PACAP mAb) first-in-human regulatory filing
  • Q4 2026: Expected closing of InMed-Mentari reverse merger (target Dec 31, 2026)
  • Q1 2027: MT-002 first-in-human regulatory filing expected
  • 2027: MT-002 Phase 1 healthy volunteer data expected
  • 2028: MT-001 Phase 2a proof-of-concept data expected

Source Filing

The SecBot filing or press-release report that triggered this drug report:

InMed Pharmaceuticals Inc. S-4 INM ·Originating report

Sources · 12

Hover a chip for the title
1 inmedpharma.com2 biospace.com3 benzinga.com4 rallies.ai5 synapse.patsnap.com6 adisinsight.springer.com7 tipranks.com8 prnewswire.com9 pennystocksunited.com10 sec.gov11 biopharmadive.com12 mentaritx.com